Amgen restructures to focus resources on late-stage drugs

10/19/2011 | Los Angeles Times (tiered subscription model)

Amgen said it is eliminating about 380 positions in research and development to focus resources on its late-stage drug pipeline. "It's very expensive to conduct clinical trials," said spokeswoman Mary Klem. "The patient population gets bigger at each phase. That's the crux of what is causing us to make these strategic changes."

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL